0001209191-22-051370.txt : 20220927
0001209191-22-051370.hdr.sgml : 20220927
20220927164631
ACCESSION NUMBER: 0001209191-22-051370
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220923
FILED AS OF DATE: 20220927
DATE AS OF CHANGE: 20220927
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Decheng Capital China Life Sciences USD Fund III, L.P.
CENTRAL INDEX KEY: 0001736814
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 221271654
BUSINESS ADDRESS:
STREET 1: UGLAND HOUSE, PO BOX 309
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
BUSINESS PHONE: 345-949-8066
MAIL ADDRESS:
STREET 1: UGLAND HOUSE, PO BOX 309
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Decheng Capital Management III (Cayman), LLC
CENTRAL INDEX KEY: 0001747821
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 221271653
BUSINESS ADDRESS:
STREET 1: PO BOX 309
STREET 2: UGLAND HOUSE
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
BUSINESS PHONE: 345-949-8066
MAIL ADDRESS:
STREET 1: PO BOX 309
STREET 2: UGLAND HOUSE
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-23
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001736814
Decheng Capital China Life Sciences USD Fund III, L.P.
UGLAND HOUSE, PO BOX 309
GRAND CAYMAN
E9
KY1-1104
CAYMAN ISLANDS
0
0
1
0
0001747821
Decheng Capital Management III (Cayman), LLC
UGLAND HOUSE, PO BOX 309
GRAND CAYMAN
E9
KY1-1104
CAYMAN ISLANDS
0
0
1
0
Common Stock
2022-09-23
4
A
0
639456
7.35
A
5347744
D
Common Stock
2022-09-23
4
A
0
1360544
7.35
A
1360544
I
See footnote
The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
Decheng Capital China Life Sciences USD Fund III, L.P., By Decheng Capital Management III (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
2022-09-27
Decheng Capital Management III (Cayman), LLC, By /s/ Xiangmin Cui, Manager
2022-09-27